Navigation Links
Biomoda Hires Senior Scientist to Expand Research & Development Effort
Date:1/11/2008

ALBUQUERQUE, N.M., Jan. 11 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, announced today Dr. Stephen M. Gomez has joined Biomoda as a Senior Research Specialist focused on the company's efforts to commercialize its assay for the early detection of lung cancer.

Dr. Gomez most recently worked as an associate research scientist at Lovelace Respiratory Research Institute in Albuquerque. He was an instructor in genetics at the University of New Mexico and consultant to national laboratories and UCLA. He is the author of nearly a dozen publications on proteomics and photosystems including his dissertation at the University of California, Los Angeles, on pigment-binding proteins.

"Dr. Gomez's experience and expertise in molecular, cell and development biology is of particular importance and use at Biomoda where we have developed a mechanism that preferentially binds to cancer cells and glows red under a microscope for easy and accurate detection of the disease," explained John Cousins, President of Biomoda. "I am pleased to have him working side-by-side with our team of exceptional scientists in the development and application of our assay by the medical community."

Dr. Gomez was awarded a Masters of Biology by the University of California before going on the get his Ph.D. in Molecular, Cell and Development Biology from the same institution. He holds a bachelors degree in biology from the California Institute of Technology, Pasadena.

Biomoda's patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

Contact: John Cousins

(505) 821-0875


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biomoda Announces Collaborative Agreement With New Mexico Tech
2. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
3. Biomoda Hires Manzano Strategies LLC to Spearhead Government Affairs Efforts
4. WallSt.net Announces Upcoming Interview With CEO of Biomoda
5. Ventria Expands Team and Hires Kansan as Director of Bioprocessing Operations
6. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
7. MedImmune Announces Seven Key Promotions and New Hires
8. Diplomat Specialty Pharmacy Hires Vice President of Managed Markets
9. Valeritas Hires Senior Account Management Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
10. Phlo Affiliate Hires Chief Marketing Officer With Extensive Global Experience
11. Valeritas Hires Trade and Distribution Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the ... to their offering. ... The Global Market for Bioproducts Should Reach ... a CAGR of 8.9%, This research report ... seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and ...
(Date:3/23/2017)... Colo. , March 23, 2017  GlobeImmune, Inc. ... agreement for the sale of 12,835,490 shares of its ... NantWorks  ecosystem of companies. In connection with the sale of ... $100,000 in cash and issue to GlobeImmune 200,000 shares, ... stock. "We are pleased to enter ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... Colo. , March 23, 2017  Agriculture technology ... Series A financing and note conversion to commercialize its ... Planet is focused on developing products that are simultaneously ... $30 million in the last 18 months. This latest ... North Bridge Venture Partners. The company,s ...
Breaking Biology Technology:
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or against ... (PRNewsFoto/Dermalog Identification Systems) ... Matching" is the fastest software for biometric Face Matching on the market. The ...
(Date:3/7/2017)... March 7, 2017   HireVue , the leading ... companies identify the best talent, faster, today announced the ... Officer (CSO) and Diana Kucer as Chief ... seasoned executive team poised to drive continued growth in ... a year of record bookings in 2017. ...
Breaking Biology News(10 mins):